SURMOUNT-MMO design published: the first incretin outcome trial covering primary prevention

The design and rationale for SURMOUNT-MMO, a large outcome trial of tirzepatide (sold as Mounjaro and Zepbound), has been published in the peer-reviewed journal Obesity ^[1]. The paper describes an event-driven trial enrolling 15,374 adults with obesity who do not have diabetes, at 664 sites in 27 countries, and it is the first outcome trial of an incretin drug to enroll people who have not yet developed cardiovascular disease ^[1].

That last point is the reason the trial is being watched closely. Earlier cardiovascular outcome trials of GLP-1 and related drugs generally required participants to already have established heart disease or another high-risk condition. SURMOUNT-MMO instead moves into what researchers call primary prevention — testing whether treating obesity itself can head off serious illness before it starts ^[1].

What the trial is measuring

The trial uses a five-component primary endpoint that includes death from any cause ^[1]. Combining several types of events into one endpoint is standard practice in large outcome trials, because it lets a study accumulate enough events to answer the question in a reasonable time. Including all-cause death is notable: it is a hard, unambiguous outcome that cannot be influenced by how investigators classify a cause of death.

Because the trial is event-driven rather than fixed in length, it continues until a pre-specified number of endpoint events has occurred rather than ending on a set calendar date ^[1]. The specific components beyond all-cause death, the target number of events, and the expected readout date have not been detailed here.

The author list spans academic cardiology, endocrinology, hepatology and surgery, including Carolyn S. P. Lam of Duke-National University of Singapore Medical School as corresponding author and Steven E. Nissen of the Cleveland Clinic Coordinating Center for Clinical Research, alongside employees of Eli Lilly and Company, which makes tirzepatide ^[1]. The design paper appears in Obesity Volume 33, Issue 9, pages 1645–1656, accompanied by a commentary from Naveed Sattar titled "From Weight Loss to Multimorbidity Prevention: Framing the Anticipated Contributions of SURMOUNT-MMO," first published online July 30, 2025 ^[1]. The trial is registered on ClinicalTrials.gov as NCT05556512 ^[2].

Why it matters for patients

For people in the United States, coverage is often the practical barrier to these medications, and coverage decisions increasingly hinge on proof that a drug prevents expensive, serious events rather than simply reducing weight. A trial designed around death and major illness in adults with obesity and no diabetes speaks directly to the largest group of people who might be considered for treatment — and to the group insurers have been most reluctant to cover.

It also matters for how the drugs are framed. Much of the public conversation about tirzepatide and semaglutide centers on pounds lost. An outcome trial asks a different question: does treating obesity with this drug change how long and how well people live? That question has not been answered for a primary-prevention population, and the design paper describes only the plan, not results ^[1].

One caution: publishing a trial design says nothing about whether the treatment works. Results could show benefit, no benefit, or harms that outweigh benefit. The size of the trial — 15,374 participants across 27 countries — reflects how many people and how much time are needed to detect differences in death and major events, not a prediction of the outcome ^[1].

What happens next

The trial continues until its pre-specified number of events accrues ^[1]. A completion or readout date has not been reported. Until results are published, any claim that tirzepatide prevents death or major illness in people with obesity but without heart disease or diabetes remains untested.

Patients weighing these medications should discuss their own risks, benefits and coverage with a clinician; this article describes a study design and is not guidance about treatment.